** Shares of Incyte INCY.O rise 3% to $61.33 premarket

** Drugmaker's Q1 adj. EPS of $1.16 beats estimates of $1.02 - LSEG data

** Its Q1 revenue of $1.05 bln comes above estimates of $993.1 mln

** Co expects annual sales of key drug Jakafi to be between $2.95 bln and $3 bln, up from prior range of $2.93 bln to $2.98 bln

** Up to last close, stock had fallen 13.8% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))